AIM: To investigate the therapeutic effects of Fuzheng Yiliu (strengthening the body resistance to inhibit tumor) decoction combined with chemotherapy on the patients with intermediate and late stage gastrointestinal ...AIM: To investigate the therapeutic effects of Fuzheng Yiliu (strengthening the body resistance to inhibit tumor) decoction combined with chemotherapy on the patients with intermediate and late stage gastrointestinal cancer. METHODS: Sixty patients were randomly divided into treatment group (chemotherapy combined with Fuzheng Yiliu decoction) and control group (chemotherapy alone). Four indexes, including the tumor recent remission rate (RR), the change of main symptoms, the toxic and side effects caused by chemotherapy and the change of performance status, were observed in the patients. Peripheral blood contents of CD3+, CD4+, CD8+ cells, CD4+/CD8+ and soluble interleukin-2 receptor (sIL-2R) were tested before and after treatment and the values were compared with those of healthy peoples. RESULTS: The improving rate of main symptoms (69.6%) and performance status (56.7%) were significantly higher in the treatment group than in the control group (34.8%, 26.7%, P<0.05). The occurrence rates of grade II toxic and side-effects on both bone marrow (13.3%) and digestive tract (30%) were lower in the treatment group compared to the control group (36.7%, 63.3%, P<0.05). Before treatment, the proportion of CD3+, CD4+ and CD4+/CD8+ decreased and the proportion of CD8+ and SIL-2R raised markedly both in the control group and treatment group as compared to the healttiy people. After treatment, that increased of CD3+, CD4+, CD4+/CD8+ increased (62.25±10.01% vs 68.31±9.72%, 36.83±10.44% vs 42.6±9.62%, 1.24±0.65 vs l.66±0.85, P<0.05) and the values of CD8+ and sIL-2R decreased obviously (33.06±7.69% vs 29.24±6.25%, 588.23±216.86 U/mL vs 475.87±211.36 U/mL,P<0.05) in the treatment group, whereas these values were opposite in the control group (64.22±6.91% vs60.63±5.75%,35.62±7.49% vs31.53±5.53%, 32.95±8.28% vs 37.14±7.48%, 1.17±0.43 vs 0.94±0.43, 573.63±214.32 U/mL vs 692.17?21.33 U/mL, P<0.05). CONCLUSION: Fuzheng Yiliu decoction can enhance therapeutic effects of chemotherapy on malignant gastrointestinal tumor, and also reduce the toxic and side effects on bone marrow and digestive tract, thereby improving the quality of life and cellular immunity in patients with malignant gastrointestinal tumor.展开更多
Objective：To study the inhibitory effect of Fuzheng Yiliu Granule（扶正抑瘤颗粒,FYG） on hepatocellular cancer（HCC） and investigate the mechanism mediating its bioactivity.Methods：H22 tumor-bearing ICR mice were t...Objective：To study the inhibitory effect of Fuzheng Yiliu Granule（扶正抑瘤颗粒,FYG） on hepatocellular cancer（HCC） and investigate the mechanism mediating its bioactivity.Methods：H22 tumor-bearing ICR mice were treated with FYG[3.6 g/（kg·d）]for 5 days.Tumor volume and tumor weight,percentages of CD3~＋,CD4~＋,CD8~＋,and natural killer（NK） cells in peripheral blood,tumor apoptosis and serum levels of interleukin-2（IL-2）,and tumor necrosis factor-α（TNF-α） were evaluated.FYG-containing serum was prepared from SD rats treated for 7 days[high dose 3.6 g/（kg·d）;middle dose 1.8 g/（kg·d）;low dose 0.9 g/（kg·d）].Cell cycle,cell viability,and apoptosis were evaluated after HepG2 cell line was cultured in FYG-containing serum for 48 h.The levels of IL-2 and TNF-αin FYG-containing serum were also determined.Results：FYG produced a potent antitumor effect（P0.01） and induced marked apoptosis of the tumor tissue（P0.05）.Mice treated with FYG had higher percentages of CD3~＋ and CD4~＋（P0.05）,and more NK cells（P0.01） in the peripheral blood than those in the animals treated with normal saline.Mice receiving FYG had the highest serum levels of IL-2 and TNF-α（P0.01）.High-dose FYG-containing serum significantly decreased HepG2 cell viability,inhibited cell proliferation（P0.05）,and induced apoptosis（P0.01）.In addition,the levels of IL-2 and TNF-αof highdose -containing serum were higher than the blank serum（P0.01）.Conclusion：FYG could inhibit HCC growth by regulating immune function and inducing apoptosis of tumor cells in vivo and in vitro.展开更多
文摘AIM: To investigate the therapeutic effects of Fuzheng Yiliu (strengthening the body resistance to inhibit tumor) decoction combined with chemotherapy on the patients with intermediate and late stage gastrointestinal cancer. METHODS: Sixty patients were randomly divided into treatment group (chemotherapy combined with Fuzheng Yiliu decoction) and control group (chemotherapy alone). Four indexes, including the tumor recent remission rate (RR), the change of main symptoms, the toxic and side effects caused by chemotherapy and the change of performance status, were observed in the patients. Peripheral blood contents of CD3+, CD4+, CD8+ cells, CD4+/CD8+ and soluble interleukin-2 receptor (sIL-2R) were tested before and after treatment and the values were compared with those of healthy peoples. RESULTS: The improving rate of main symptoms (69.6%) and performance status (56.7%) were significantly higher in the treatment group than in the control group (34.8%, 26.7%, P<0.05). The occurrence rates of grade II toxic and side-effects on both bone marrow (13.3%) and digestive tract (30%) were lower in the treatment group compared to the control group (36.7%, 63.3%, P<0.05). Before treatment, the proportion of CD3+, CD4+ and CD4+/CD8+ decreased and the proportion of CD8+ and SIL-2R raised markedly both in the control group and treatment group as compared to the healttiy people. After treatment, that increased of CD3+, CD4+, CD4+/CD8+ increased (62.25±10.01% vs 68.31±9.72%, 36.83±10.44% vs 42.6±9.62%, 1.24±0.65 vs l.66±0.85, P<0.05) and the values of CD8+ and sIL-2R decreased obviously (33.06±7.69% vs 29.24±6.25%, 588.23±216.86 U/mL vs 475.87±211.36 U/mL,P<0.05) in the treatment group, whereas these values were opposite in the control group (64.22±6.91% vs60.63±5.75%,35.62±7.49% vs31.53±5.53%, 32.95±8.28% vs 37.14±7.48%, 1.17±0.43 vs 0.94±0.43, 573.63±214.32 U/mL vs 692.17?21.33 U/mL, P<0.05). CONCLUSION: Fuzheng Yiliu decoction can enhance therapeutic effects of chemotherapy on malignant gastrointestinal tumor, and also reduce the toxic and side effects on bone marrow and digestive tract, thereby improving the quality of life and cellular immunity in patients with malignant gastrointestinal tumor.
基金Supported by CHEN Ke-ji Integrative Medicine Development Fund(No.CKJ2010020)International Science Joint Project of the Ministry of Science and Technology of the People's Republic of China(No.2008DFA32200)Project of Department of Education of Fujian Province(No.JA09136)
文摘Objective：To study the inhibitory effect of Fuzheng Yiliu Granule（扶正抑瘤颗粒,FYG） on hepatocellular cancer（HCC） and investigate the mechanism mediating its bioactivity.Methods：H22 tumor-bearing ICR mice were treated with FYG[3.6 g/（kg·d）]for 5 days.Tumor volume and tumor weight,percentages of CD3~＋,CD4~＋,CD8~＋,and natural killer（NK） cells in peripheral blood,tumor apoptosis and serum levels of interleukin-2（IL-2）,and tumor necrosis factor-α（TNF-α） were evaluated.FYG-containing serum was prepared from SD rats treated for 7 days[high dose 3.6 g/（kg·d）;middle dose 1.8 g/（kg·d）;low dose 0.9 g/（kg·d）].Cell cycle,cell viability,and apoptosis were evaluated after HepG2 cell line was cultured in FYG-containing serum for 48 h.The levels of IL-2 and TNF-αin FYG-containing serum were also determined.Results：FYG produced a potent antitumor effect（P0.01） and induced marked apoptosis of the tumor tissue（P0.05）.Mice treated with FYG had higher percentages of CD3~＋ and CD4~＋（P0.05）,and more NK cells（P0.01） in the peripheral blood than those in the animals treated with normal saline.Mice receiving FYG had the highest serum levels of IL-2 and TNF-α（P0.01）.High-dose FYG-containing serum significantly decreased HepG2 cell viability,inhibited cell proliferation（P0.05）,and induced apoptosis（P0.01）.In addition,the levels of IL-2 and TNF-αof highdose -containing serum were higher than the blank serum（P0.01）.Conclusion：FYG could inhibit HCC growth by regulating immune function and inducing apoptosis of tumor cells in vivo and in vitro.
